587 related articles for article (PubMed ID: 23467199)
41. Peginterferon alfa-2a with or without low-dose ribavirin for treatment-naive patients with hepatitis C virus genotype 2 receiving haemodialysis: a randomised trial.
Liu CH; Liu CJ; Huang CF; Lin JW; Dai CY; Liang CC; Huang JF; Hung PH; Tsai HB; Tsai MK; Lee CY; Chen SI; Yang SS; Su TH; Yang HC; Chen PJ; Chen DS; Chuang WL; Yu ML; Kao JH
Gut; 2015 Feb; 64(2):303-11. PubMed ID: 24747867
[TBL] [Abstract][Full Text] [Related]
42. Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): a randomised, double-blind, placebo-controlled phase 3 trial.
Manns M; Marcellin P; Poordad F; de Araujo ES; Buti M; Horsmans Y; Janczewska E; Villamil F; Scott J; Peeters M; Lenz O; Ouwerkerk-Mahadevan S; De La Rosa G; Kalmeijer R; Sinha R; Beumont-Mauviel M
Lancet; 2014 Aug; 384(9941):414-26. PubMed ID: 24907224
[TBL] [Abstract][Full Text] [Related]
43. Virological escape in HCV genotype-1-infected patients receiving daclatasvir plus ribavirin and peginterferon alfa-2a or alfa-2b.
McPhee F; Hernandez D; Zhou N; Yu F; Ueland J; Monikowski A; Chayama K; Toyota J; Izumi N; Yokosuka O; Kawada N; Osaki Y; Hughes EA; Watanabe H; Ishikawa H; Kumada H
Antivir Ther; 2014; 19(5):479-90. PubMed ID: 24448487
[TBL] [Abstract][Full Text] [Related]
44. Platelet count is associated with sustained virological response rates in treatments for chronic hepatitis C.
Jun BG; Park EJ; Lee WC; Jang JY; Jeong SW; Kim YD; Cheon GJ; Cho YS; Lee SH; Kim HS; Lee YN; Kim SG; Kim YS; Kim BS
Korean J Intern Med; 2019 Sep; 34(5):989-997. PubMed ID: 29529840
[TBL] [Abstract][Full Text] [Related]
45. Induction pegylated interferon alfa-2a and high dose ribavirin do not increase SVR in heavy patients with HCV genotype 1 and high viral loads.
Reddy KR; Shiffman ML; Rodriguez-Torres M; Cheinquer H; Abdurakhmanov D; Bakulin I; Morozov V; Silva GF; Geyvandova N; Stanciu C; Rabbia M; McKenna M; Thommes JA; Harrison SA;
Gastroenterology; 2010 Dec; 139(6):1972-83. PubMed ID: 20816836
[TBL] [Abstract][Full Text] [Related]
46. Treatment of chronic hepatitis C with pegylated interferon and ribavirin in treatment-naive patients in 'true life': a plea in favor of independent postmarketing evaluations.
Pariente A; Lahmek P; Duprat C; Denis J; Faroux R; Renou C; Nalet B; Morin T; Cadranel JF;
Eur J Gastroenterol Hepatol; 2010 Nov; 22(11):1297-302. PubMed ID: 20964260
[TBL] [Abstract][Full Text] [Related]
47. Responses to peginterferon alfa-2a vs alfa-2b plus ribavirin in a Mexican population with chronic hepatitis C.
Sandoval-Ramirez JL; Mata-Marín JA; Huerta García G; Gaytán-Martínez JE
J Infect Dev Ctries; 2015 Mar; 9(3):267-73. PubMed ID: 25771464
[TBL] [Abstract][Full Text] [Related]
48. Interferon-λ3 polymorphisms in pegylated-interferon-α plus ribavirin therapy for genotype-2 chronic hepatitis C.
Ishiguro H; Abe H; Seki N; Sugita T; Aida Y; Itagaki M; Sutoh S; Shimada N; Furihata T; Tsubota A; Aizawa Y
World J Gastroenterol; 2015 Apr; 21(13):3904-11. PubMed ID: 25852275
[TBL] [Abstract][Full Text] [Related]
49. Peginterferon Alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons.
Chung RT; Andersen J; Volberding P; Robbins GK; Liu T; Sherman KE; Peters MG; Koziel MJ; Bhan AK; Alston B; Colquhoun D; Nevin T; Harb G; van der Horst C;
N Engl J Med; 2004 Jul; 351(5):451-9. PubMed ID: 15282352
[TBL] [Abstract][Full Text] [Related]
50. Interferon-λ polymorphisms and response to pegylated interferon in Iranian hepatitis C patients.
Haj-Sheykholeslami A; Keshvari M; Sharafi H; Pouryasin A; Hemmati K; Mohammadzadehparjikolaei F
World J Gastroenterol; 2015 Aug; 21(29):8935-42. PubMed ID: 26269684
[TBL] [Abstract][Full Text] [Related]
51. Induction pegylated interferon alfa-2b in combination with ribavirin in patients with genotypes 1 and 4 chronic hepatitis C: a prospective, randomized, multicenter, open-label study.
Brady DE; Torres DM; An JW; Ward JA; Lawitz E; Harrison SA
Clin Gastroenterol Hepatol; 2010 Jan; 8(1):66-71.e1. PubMed ID: 19747986
[TBL] [Abstract][Full Text] [Related]
52. Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial.
Carrat F; Bani-Sadr F; Pol S; Rosenthal E; Lunel-Fabiani F; Benzekri A; Morand P; Goujard C; Pialoux G; Piroth L; Salmon-Céron D; Degott C; Cacoub P; Perronne C;
JAMA; 2004 Dec; 292(23):2839-48. PubMed ID: 15598915
[TBL] [Abstract][Full Text] [Related]
53. Efficacy of peginterferon alpha-2A and ribavirin combination therapy in treatment-naive Estonian patients with chronic hepatitis C.
Brjalin V; Salupere R; Tallo T; Kuznetsova T; Priimägi L; Tefanova V
Cent Eur J Public Health; 2012 Jun; 20(2):150-5. PubMed ID: 22966742
[TBL] [Abstract][Full Text] [Related]
54. Multicenter comparison of PEG-IFN α2a or α2b plus ribavirin for treatment-naïve HCV patient in Korean population.
Jin YJ; Lee JW; Lee JI; Park SH; Park CK; Kim YS; Jeong SH; Kim YS; Kim JH; Hwang SG; Rim KS; Yim HJ; Cheong JY; Cho SW; Lee JS; Park YM; Jang JW; Lee CK; Sohn JH; Yang JM; Han S
BMC Gastroenterol; 2013 Apr; 13():74. PubMed ID: 23627926
[TBL] [Abstract][Full Text] [Related]
55. Daclatasvir and Peginterferon/Ribavirin for Black/African-American and Latino Patients with HCV infection.
Rodriguez-Torres M; Lawitz E; Yangco B; Jeffers L; Han SH; Thuluvath PJ; Rustgi V; Harrison S; Ghalib R; Vierling JM; Luketic V; Zamor PJ; Ravendhran N; Morgan TR; Pearlman B; O'Brien C; Khallafi H; Pyrsopoulos N; Kong G; McPhee F; Yin PD; Hughes E; Treitel M
Ann Hepatol; 2016 Nov-Dec 2016; 15(6):834-845. PubMed ID: 27740516
[TBL] [Abstract][Full Text] [Related]
56. Incidence of neutropenia and infections during combination treatment of chronic hepatitis C with pegylated interferon alfa-2a or alfa-2b plus ribavirin.
Antonini MG; Babudieri S; Maida I; Baiguera C; Zanini B; Fenu L; Dettori G; Manno D; Mura MS; Carosi G; Puoti M
Infection; 2008 Jun; 36(3):250-5. PubMed ID: 18458815
[TBL] [Abstract][Full Text] [Related]
57. Effect of ribavirin in genotype 1 patients with hepatitis C responding to pegylated interferon alfa-2a plus ribavirin.
Bronowicki JP; Ouzan D; Asselah T; Desmorat H; Zarski JP; Foucher J; Bourlière M; Renou C; Tran A; Melin P; Hézode C; Chevalier M; Bouvier-Alias M; Chevaliez S; Montestruc F; Lonjon-Domanec I; Pawlotsky JM
Gastroenterology; 2006 Oct; 131(4):1040-8. PubMed ID: 17030174
[TBL] [Abstract][Full Text] [Related]
58. Response predictors and clinical benefits of hepatitis C retreatment with pegylated interferon and ribavirin in HIV/HCV coinfection.
Peribañez-Gonzalez M; da Silva MH; Vilar FC; Seixas-Santos Nastri AC; Ferreira PA; Focaccia R; Mendes Correa MC
Ann Hepatol; 2013; 12(2):228-35. PubMed ID: 23396734
[TBL] [Abstract][Full Text] [Related]
59. High sustained virologic response rates in children with chronic hepatitis C receiving peginterferon alfa-2b plus ribavirin.
Wirth S; Ribes-Koninckx C; Calzado MA; Bortolotti F; Zancan L; Jara P; Shelton M; Kerkar N; Galoppo M; Pedreira A; Rodriguez-Baez N; Ciocca M; Lachaux A; Lacaille F; Lang T; Kullmer U; Huber WD; Gonzalez T; Pollack H; Alonso E; Broue P; Ramakrishna J; Neigut D; Valle-Segarra AD; Hunter B; Goodman Z; Xu CR; Zheng H; Noviello S; Sniukiene V; Brass C; Albrecht JK
J Hepatol; 2010 Apr; 52(4):501-7. PubMed ID: 20189674
[TBL] [Abstract][Full Text] [Related]
60. Rapid virological response tailors the duration of treatment in hepatitis C virus genotype 3 patients treated with pegylated interferon alfa-2a and ribavirin in Pakistan.
Gill U; Aziz H; Gill ML
Int J Infect Dis; 2013 Nov; 17(11):e1017-21. PubMed ID: 23896656
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
